Arrowhead Pharmaceuticals (ARWR) Share-based Compensation (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Share-based Compensation data on file, last reported at $16.7 million in Q1 2026.

• Quarterly Share-based Compensation rose 4.01% year-over-year to $16.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $68.2 million (up 0.61% YoY) and the FY2025 annual result came in at $63.4 million, down 14.33% from the prior year.
• Share-based Compensation fell to $16.7 million in Q1 2026, from $19.4 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $33.4 million in Q2 2022 to a low of $13.0 million in Q2 2025.
• A 5-year average of $19.6 million and a median of $19.1 million in 2025 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation soared 53.72% — and 2023, when it tumbled 40.26%.
• Tracing ARWR's Share-based Compensation over 5 years: stood at $19.4 million in 2022, then grew by 1.57% to $19.7 million in 2023, then dropped by 22.77% to $15.2 million in 2024, then gained by 27.37% to $19.4 million in 2025, then slipped by 13.94% to $16.7 million in 2026.
• The last three Share-based Compensation figures came in at $16.7 million (Q1 2026), $19.4 million (Q4 2025), and $19.1 million (Q3 2025), per Business Quant data.